Dr. Attie joins the company from his most recent position of chief medical officer at biotechnology company Imara. He has held additional leadership roles in his more than 30-year career at Altus Pharmaceuticals, Insmed and Genentech, according to an Oct. 18 Versanis news release.
The promotion comes as the company looks to expand its lead obesity drug candidate, bimagrumab.
“I look forward to applying my medical research experience and successful track record advancing therapeutic programs through regulatory approval to design and lead Versanis’ development programs,” Dr. Attie said. “Bimagrumab is an exceptional agent that has the potential to drive substantial weight loss, improve body composition, and result in sustained long-term clinical benefit for people with obesity and cardiometabolic diseases.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.